Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has said that it will only approve Avanir's Zenvia in involuntary emotional expression disorder if the company provides additional safety and efficacy data.
Subscribe to our email newsletter
The company submitted a new drug application in January 2006, seeking to market Zenvia for the treatment of involuntary emotional expression disorder (IEED) in patients with neurologic diseases and brain injuries. The communication from the FDA indicates that Avanir’s application is approvable, subject to the FDA and Avanir reaching agreement on what additional safety and efficacy data will be required.
Avanir said that until it is able to meet with the agency, it can not comment on the specifics of the approvable requirements. Additionally, the company said it cannot be certain that once it has met with the FDA that it will choose to continue with the development of Zenvia as previously planned.
Avanir has also initiated a phase III clinical trial with Zenvia as a potential treatment for patients with painful diabetic neuropathy.